Among the 33 tumor samples tested, 12 (36.4%) had KRAS mutations at the respective codons: 83.3% (10/12) were single-point mutations at codon 12, while 16.7% (2/12) mutations were observed at codon 13. This evidence concerns the gene KRAS and neoplasm.